A phase I study to assess safety, tolerance and pharmacokinetics of oral dosing Icotinib Hydrochloride Tablets.

Trial Profile

A phase I study to assess safety, tolerance and pharmacokinetics of oral dosing Icotinib Hydrochloride Tablets.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Icotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Zhejiang Beta Pharma
  • Most Recent Events

    • 21 May 2012 Status changed from recruiting to completed as reported by Chinese Clinical Trial Register.
    • 15 Nov 2011 Status changed from completed to recruiting as reported by Chinese Clinical Trial Register record.
    • 11 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top